177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient with Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation
- Assadi,, M
- Pirayesh,, E
- Rekabpour,, S.J
- Zohrabi,, F
- Jafari,, E
- Nabipour,, I
- Esmaili,, A
- Amini,, A
- Ahmadzadehfar,, H
Publication date
January 2019
DOI Publisher
Ovid Technologies (Wolters Kluwer Health)Abstract
We presented a promising result of radionuclide therapy using 177Lu-PSMA and 177Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. © 2019 Wolters Kluwer Health, Inc. All rights reserved
Add to ORKG